Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILDR + PD-1/PD-L1 in resistant metastatic solid tumors
NCT07071103Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial in metastatic solid tumor, lung cancer and esophageal cancer (3 arms). Primary endpoints: Objective Response Rate at 24 weeks, Disease Control Rate at 24 weeks and 2 more. Started Sep 2025; status: recruiting.
02
Conditions
metastatic solid tumorlung canceresophageal cancer
Beyond the preview
Go deeper on NCT07071103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071103.